{"id":95040,"date":"2026-10-14T13:35:47","date_gmt":"2026-10-14T13:35:47","guid":{"rendered":"https:\/\/www.boccard.com\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/"},"modified":"2026-10-15T16:16:08","modified_gmt":"2026-10-15T16:16:08","slug":"anticorps-monoclonaux-utilisations-production-et-avancees-recentes","status":"publish","type":"post","link":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/","title":{"rendered":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"95040\" class=\"elementor elementor-95040 elementor-95015\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-4160cf5c elementor-section-full_width elementor-section-content-middle elementor-section-height-default elementor-section-height-default\" data-id=\"4160cf5c\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-c3f007e\" data-id=\"c3f007e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1335b6c elementor-widget__width-initial elementor-view-default elementor-position-block-start elementor-mobile-position-block-start elementor-widget elementor-widget-icon-box\" data-id=\"1335b6c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-box.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-icon-box-wrapper\">\n\n\t\t\t\t\t\t<div class=\"elementor-icon-box-icon\">\n\t\t\t\t<span  class=\"elementor-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" id=\"Calque_1\" x=\"0px\" y=\"0px\" viewBox=\"0 0 71 64\" style=\"enable-background:new 0 0 71 64;\" xml:space=\"preserve\"><style type=\"text\/css\">\t.st0{opacity:0.1;fill-rule:evenodd;clip-rule:evenodd;fill:#FFFFFF;enable-background:new    ;}\t.st1{fill:#FFFFFF;}<\/style><g id=\"Home-V7\">\t<g id=\"Group-17\">\t\t<path id=\"Fill-4-Copy-4\" class=\"st0\" d=\"M55.2,61.4c4-0.2,7.9-0.9,11.8-1.8c0.6-0.1,1-0.5,1.1-1.1c1.4-3.9,2.3-8,2.4-12.2    c0.3-7.1-1.6-14.2-5.3-20.3C59,16,50.2,10.1,38.9,8.7c-18.7-2.5-35.1,10.1-39,28c-0.2,0.5-0.1,1.1,0.3,1.5    c9,10.4,21,17.9,34.3,21.3c5.1,1.3,10.3,2,15.6,2C51.8,61.6,53.5,61.5,55.2,61.4\"><\/path>\t<\/g><\/g><path class=\"st1\" d=\"M53.7,15.1c0.4,0.4,1.1,0.4,1.5,0c0,0,0,0,0-0.1c0.4-0.5,0.4-1.2-0.1-1.6c-1.5-1.3-2.8-2.9-3.8-4.6h10.4  c0.6,0,1.1-0.5,1.1-1.1c0-0.6-0.5-1.1-1.1-1.1H50.5c-0.4-1.1-0.6-2.2-0.6-3.3c0-0.6-0.5-1.1-1.1-1.2c-0.3,0-0.6,0.1-0.8,0.3l0,0  c-0.2,0.2-0.3,0.5-0.3,0.9C47.7,7.5,49.8,11.6,53.7,15.1z\"><\/path><path class=\"st1\" d=\"M53.6,43.8c0.4,0.4,1.1,0.4,1.5,0l0,0c0.4-0.5,0.4-1.2-0.1-1.6c-3.4-3-5.2-6.5-5.2-10.1l0,0  c0-5,3.5-9.8,9.9-13.4c7.1-4,11-9.5,11-15.4c-0.1-0.6-0.6-1.1-1.2-1c-0.5,0.1-1,0.5-1,1c0,5-3.5,9.8-9.8,13.4c-7.1,4-11,9.5-11,15.3  l0,0C47.6,36.2,49.7,40.3,53.6,43.8z\"><\/path><path class=\"st1\" d=\"M64.4,48.9c-0.4-0.4-1.1-0.5-1.6,0c-0.4,0.4-0.5,1.1,0,1.6c0,0,0.1,0.1,0.1,0.1c1.5,1.3,2.8,2.9,3.8,4.6H56.3  c-0.6,0.1-1.1,0.6-1,1.2c0.1,0.5,0.5,1,1,1h11.3c0.4,1.1,0.5,2.2,0.6,3.3c0,0.6,0.5,1.1,1.1,1.1c0.6,0,1.1-0.5,1.1-1.1  C70.4,56.5,68.3,52.4,64.4,48.9z\"><\/path><path class=\"st1\" d=\"M70.7,32L70.7,32c0-4.2-2-8.3-5.9-11.8c-0.5-0.4-1.2-0.4-1.6,0.1c0,0,0,0,0,0c-0.4,0.5-0.4,1.2,0.1,1.6  c0,0,0,0,0,0c1.5,1.3,2.8,2.9,3.7,4.6H56.8c-0.6,0.1-1.1,0.6-1,1.2c0.1,0.5,0.5,1,1,1H68c0.3,1.1,0.5,2.1,0.5,3.2l0,0  c0,1.1-0.2,2.2-0.5,3.2H56.8c-0.6,0.1-1.1,0.6-1,1.2c0.1,0.5,0.5,1,1,1H67c-1.6,2.9-4.4,5.7-8.4,7.9c-7.1,4-11,9.5-11,15.4  c0,0.3,0.1,0.6,0.3,0.8l0,0c0.4,0.4,1.1,0.4,1.6,0c0.2-0.2,0.3-0.5,0.3-0.8c0-5,3.5-9.8,9.9-13.4C66.8,43.3,70.7,37.8,70.7,32z\"><\/path><path class=\"st1\" d=\"M31.7,38h-4.9v-4.9c0-0.9-0.7-1.6-1.6-1.6h-7c-0.9,0-1.6,0.7-1.6,1.6V38h-4.8c-0.9,0-1.6,0.7-1.6,1.6v7  c0,0.9,0.7,1.6,1.6,1.6h4.9V53c0,0.9,0.7,1.6,1.6,1.6h7c0.9,0,1.6-0.7,1.5-1.6v-4.8h4.9c0.9,0,1.6-0.7,1.6-1.6v-7  C33.2,38.7,32.5,38,31.7,38z M31.1,46h-6.4v6.5h-5.9V46h-6.4v-5.8h6.4v-6.4h5.9v6.5h6.4V46z\"><\/path><path class=\"st1\" d=\"M33,20.8v-3.2c2.4-0.5,4.2-2.6,4.2-5.1V7.3c0-2.9-2.3-5.2-5.2-5.2H10.9c-2.9,0-5.2,2.3-5.2,5.2v0v5.2  c0,2.5,1.8,4.6,4.2,5.1v3.2l-4.5,4.4C2.6,28,0.3,33.6,0.3,37.8v18.9c0,2.9,2.3,5.2,5.2,5.2h31.9c2.9,0,5.2-2.3,5.2-5.2V37.8  c0-4.2-2.3-9.8-5.1-12.6L33,20.8z M7.8,12.5V7.3c0-1.7,1.4-3.1,3.1-3.1H32c1.7,0,3.1,1.4,3.1,3.1l0,0v5.2c0,1.7-1.4,3.1-3.1,3.1  H10.9C9.2,15.6,7.8,14.2,7.8,12.5C7.8,12.5,7.8,12.5,7.8,12.5z M40.5,56.7c0,1.7-1.4,3.1-3.1,3.1c0,0,0,0,0,0H5.5  c-1.7,0-3.1-1.4-3.1-3.1l0,0V37.8c0-3.6,2-8.7,4.5-11l5.1-5v-2.6h18.9v2.6l5.2,5c2.7,3,4.3,6.9,4.5,11V56.7z\"><\/path><\/svg>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t<div class=\"elementor-icon-box-content\">\n\n\t\t\t\t\t\t\t\t\t<h3 class=\"elementor-icon-box-title\">\n\t\t\t\t\t\t<span  >\n\t\t\t\t\t\t\tPHARMA<br \/>&amp; BIOTECH\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-5ad2b619 bg-over elementor-hidden-mobile\" data-id=\"5ad2b619\" data-element_type=\"column\" data-e-type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-59001e41 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"59001e41\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-33345bb1\" data-id=\"33345bb1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-6a0b33c3 elementor-widget elementor-widget-text-editor\" data-id=\"6a0b33c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Les anticorps monoclonaux, ou mAb, sont des <a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/monoclonal-antibody\">prot\u00e9ines synth\u00e9tis\u00e9es en laboratoire et con\u00e7ues pour reconna\u00eetre des cibles biologiques sp\u00e9cifiques.<\/a> Leurs effets d\u00e9pendent de <a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/monoclonal-antibodies\">leur conception :<\/a> certains types peuvent interf\u00e9rer avec une voie li\u00e9e \u00e0 une maladie, aider les cellules immunitaires \u00e0 identifier une cible ou acheminer une substance th\u00e9rapeutique vers des cellules particuli\u00e8res. Cette polyvalence rend les m\u00e9dicaments \u00e0 base d\u2019anticorps pertinents dans plusieurs domaines de la m\u00e9decine, tout en cr\u00e9ant des d\u00e9fis sp\u00e9cifiques pour les \u00e9quipes charg\u00e9es de leur fabrication.<\/p><p><em>D\u00e9couvrez dans cet article \u00e0 quoi servent les anticorps monoclonaux, quelles avanc\u00e9es r\u00e9centes fa\u00e7onnent leurs applications cliniques et comment Boccard peut accompagner les producteurs dans leur fabrication \u00e0 grande \u00e9chelle !<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-38fa0fd elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"38fa0fd\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-756b356\" data-id=\"756b356\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-0eaa65d elementor-widget elementor-widget-heading\" data-id=\"0eaa65d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Que sont les anticorps monoclonaux et comment fonctionnent-ils ?<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-785f329 elementor-widget elementor-widget-heading\" data-id=\"785f329\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Pourquoi les appelle-t-on anticorps monoclonaux ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b5cf95f elementor-widget elementor-widget-text-editor\" data-id=\"b5cf95f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>Anticorps <\/strong>d\u00e9signe une prot\u00e9ine qui reconna\u00eet une cible, appel\u00e9e antig\u00e8ne, et s\u2019y lie.<\/li><li><strong>Monoclonal<\/strong> d\u00e9signe une lign\u00e9e cellulaire unique s\u00e9lectionn\u00e9e, ou clone, utilis\u00e9e pour produire des anticorps pr\u00e9sentant la m\u00eame conception de liaison \u00e0 la cible.<\/li><\/ul><p>Le terme d\u00e9crit donc leur origine commune et leur sp\u00e9cificit\u00e9.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4d39715 elementor-widget elementor-widget-heading\" data-id=\"4d39715\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Comment un anticorps monoclonal agit-il sur sa cible ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cbbf320 elementor-widget elementor-widget-text-editor\" data-id=\"cbbf320\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La caract\u00e9ristique fondamentale d\u2019un anticorps est sa capacit\u00e9 \u00e0 se lier \u00e0 une cible. Ce qui se passe apr\u00e8s cette liaison d\u00e9pend du m\u00e9dicament. Dans le traitement du cancer, par exemple, certains anticorps monoclonaux aident le syst\u00e8me immunitaire \u00e0 <a href=\"https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/monoclonal-antibodies\">reconna\u00eetre et d\u00e9truire les cellules canc\u00e9reuses. <\/a>D\u2019autres rapprochent les cellules immunitaires des cellules canc\u00e9reuses afin qu\u2019elles puissent agir contre elles. La seule liaison \u00e0 une cible ne d\u00e9crit pas tous les effets th\u00e9rapeutiques d\u2019un anticorps.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-87b4591 elementor-widget elementor-widget-heading\" data-id=\"87b4591\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Quels sont les principaux types de m\u00e9dicaments \u00e0 base d\u2019anticorps ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-31b6b16 elementor-widget elementor-widget-text-editor\" data-id=\"31b6b16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Un anticorps monoclonal conventionnel est con\u00e7u pour reconna\u00eetre une cible particuli\u00e8re. Un <a href=\"https:\/\/www.fda.gov\/media\/123313\/download\"><strong>anticorps bisp\u00e9cifique, <\/strong><\/a>par exemple, est con\u00e7u pour se lier \u00e0 deux cibles. L\u2019une de ses applications consiste \u00e0 mettre en relation une cellule canc\u00e9reuse et une cellule T, m\u00eame si les anticorps bisp\u00e9cifiques peuvent \u00eatre con\u00e7us pour d\u2019autres usages.<\/p><p>Un autre type est<a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pivekimab-sunirine-pvzy-blastic-plasmacytoid-dendritic-cell-neoplasm-ultra-rare\"><strong> l\u2019anticorps conjugu\u00e9 \u00e0 un m\u00e9dicament (ADC, antibody-drug conjugate en anglais), <\/strong><\/a>qui associe un anticorps de ciblage \u00e0 une charge m\u00e9dicamenteuse li\u00e9e. L\u2019anticorps, la charge et leur liaison sont des \u00e9l\u00e9ments distincts dans la conception du m\u00e9dicament.<\/p><p>Outre ces deux exemples, <strong>les autres classifications<\/strong> d\u2019anticorps peuvent aussi diff\u00e9rer par leur structure et par la mani\u00e8re dont leur activit\u00e9 ou leur dur\u00e9e de pr\u00e9sence dans l\u2019organisme a \u00e9t\u00e9 con\u00e7ue. Dans cet article, nous nous concentrons sur les anticorps bisp\u00e9cifiques et les ADC ainsi que sur leurs avanc\u00e9es cliniques r\u00e9centes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-d327f84 e-flex e-con-boxed e-con e-parent\" data-id=\"d327f84\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-cbe66e5 e-con-full e-flex e-con e-child\" data-id=\"cbe66e5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-944db71 e-flex e-con-boxed e-con e-parent\" data-id=\"944db71\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-17408b0 elementor-widget elementor-widget-heading\" data-id=\"17408b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Quelles maladies les m\u00e9dicaments \u00e0 base d\u2019anticorps peuvent-ils contribuer \u00e0 traiter ou \u00e0 prendre en charge ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-379d5b9 elementor-widget elementor-widget-text-editor\" data-id=\"379d5b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Le cancer<\/strong> constitue une application \u00e9tablie, puisque les anticorps monoclonaux sont utilis\u00e9s contre de nombreux types de cancer, la cible et le m\u00e9canisme variant selon le m\u00e9dicament. En juin 2026, par exemple, la Food and Drug Administration am\u00e9ricaine (FDA) a approuv\u00e9 des utilisations suppl\u00e9mentaires en premi\u00e8re ligne de <a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line\">l\u2019ADC sacituzumab govitecan<\/a> for specified groups of adults with unresectable locally advanced or metastatic triple-negative breast cancer. <a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/unresectable\">Non r\u00e9s\u00e9cable <\/a>signifie qu\u2019une tumeur ne peut pas \u00eatre retir\u00e9e par chirurgie, tandis que <a href=\"https:\/\/www.cancer.gov\/types\/breast\/breast-cancer-types\/triple-negative\">triple n\u00e9gatif<\/a> d\u00e9crit des cellules canc\u00e9reuses du sein d\u00e9pourvues de r\u00e9cepteurs aux \u0153strog\u00e8nes et \u00e0 la progest\u00e9rone et pr\u00e9sentant peu ou pas de prot\u00e9ine HER2. Les traitements conventionnels dirig\u00e9s contre ces trois marqueurs ne conviennent pas \u00e0 une tumeur qui en est d\u00e9pourvue. Dans cet exemple, l\u2019ADC utilise donc un anticorps pour cibler ces cellules canc\u00e9reuses et leur d\u00e9livrer sa charge m\u00e9dicamenteuse afin de les d\u00e9truire.<\/p><p>Au-del\u00e0 de l\u2019oncologie, les applications incluent<strong> l\u2019asthme s\u00e9v\u00e8re <\/strong>et des maladies g\u00e9n\u00e9tiques rares telles que <strong>l\u2019h\u00e9mophilie A.<\/strong> Pour la premi\u00e8re, les nouvelles autorisations de m\u00e9dicaments accord\u00e9es par la FDA en 2025 comprennent le <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761458s000lblCorrection.pdf\">d\u00e9p\u00e9mokimab <\/a>pour l\u2019asthme s\u00e9v\u00e8re caract\u00e9ris\u00e9 par un ph\u00e9notype \u00e9osinophilique. Il s\u2019agit d\u2019une forme d\u2019asthme associ\u00e9e aux \u00e9osinophiles, un type de cellule immunitaire impliqu\u00e9 dans l\u2019inflammation des voies respiratoires. Le d\u00e9p\u00e9mokimab cible l\u2019interleukine-5, une prot\u00e9ine de signalisation impliqu\u00e9e dans la biologie des \u00e9osinophiles, et agit comme traitement d\u2019entretien compl\u00e9mentaire dans la prise en charge de l\u2019asthme.<\/p><p>Dans<strong> l\u2019h\u00e9mophilie A,<\/strong> l\u2019organisme ne dispose pas d\u2019une quantit\u00e9 suffisante de facteur VIII fonctionnel, une prot\u00e9ine n\u00e9cessaire \u00e0 une coagulation normale. Une \u00e9tude men\u00e9e en 2026 a examin\u00e9 un anticorps bisp\u00e9cifique con\u00e7u pour <a href=\"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2517384\">imiter une fonction du facteur VIII activ\u00e9 <\/a>afin de pr\u00e9venir les saignements. Ses deux sites de liaison rapprochent les facteurs de coagulation IXa et X afin de soutenir le processus de coagulation.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-560b7be e-flex e-con-boxed e-con e-parent\" data-id=\"560b7be\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-083b605 elementor-widget elementor-widget-heading\" data-id=\"083b605\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Comment les anticorps monoclonaux sont-ils produits \u00e0 grande \u00e9chelle?<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d65f72a elementor-widget elementor-widget-heading\" data-id=\"d65f72a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Comment l\u2019anticorps est-il produit par culture cellulaire ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-25509c3 elementor-widget elementor-widget-text-editor\" data-id=\"25509c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La production commence par une <a href=\"https:\/\/www.fda.gov\/media\/77528\/download\">lign\u00e9e cellulaire caract\u00e9ris\u00e9e <\/a>capable de produire l\u2019anticorps souhait\u00e9. Les fabricants \u00e9tablissent des banques cellulaires, d\u00e9veloppent les cellules et les cultivent dans des conditions contr\u00f4l\u00e9es au sein de bior\u00e9acteurs.<\/p><p>Les <strong>cellules d\u2019ovaire de hamster chinois (CHO) <\/strong>constituent un exemple document\u00e9 de syst\u00e8me de production, sans \u00eatre la seule option possible. L\u2019\u00e9valuation de la qualit\u00e9 du produit par la FDA indique que <a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761181s002lbl.pdf\">l\u2019\u00e9vinacumab <\/a>est produit dans des cellules CHO. L\u2019\u00e9vinacumab est un anticorps monoclonal utilis\u00e9 pour r\u00e9duire le cholest\u00e9rol LDL chez les personnes atteintes d\u2019hypercholest\u00e9rol\u00e9mie familiale homozygote, une maladie h\u00e9r\u00e9ditaire entra\u00eenant un taux de cholest\u00e9rol tr\u00e8s \u00e9lev\u00e9.<\/p><p>La culture cellulaire constitue \u00e9galement un<strong> enjeu de qualit\u00e9. <\/strong>Dans une \u00e9tude de la FDA, les chercheurs<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7496122\/\"> ont d\u00e9lib\u00e9r\u00e9ment introduit un mycoplasme <\/a>dans une culture CHO exp\u00e9rimentale afin d\u2019en examiner les effets. Le terme <em>mycoplasme <\/em>d\u00e9signe des bact\u00e9ries susceptibles de contaminer les cultures cellulaires. La contamination \u00e9tait volontaire dans le cadre de l\u2019exp\u00e9rience et ne constitue pas une \u00e9tape pr\u00e9vue de la production d\u2019anticorps. Les chercheurs ont ensuite observ\u00e9 des modifications de certaines caract\u00e9ristiques de l\u2019anticorps produit, notamment de sa charge et de sa glycosylation. Cela souligne pourquoi les producteurs surveillent les contaminations : une culture peut continuer \u00e0 produire un anticorps alors m\u00eame que sa qualit\u00e9 \u00e9volue.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e1b93f elementor-widget elementor-widget-heading\" data-id=\"4e1b93f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Comment l\u2019anticorps est-il r\u00e9cup\u00e9r\u00e9 et purifi\u00e9 ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0d626c3 elementor-widget elementor-widget-text-editor\" data-id=\"0d626c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Apr\u00e8s la culture, l\u2019anticorps doit \u00eatre r\u00e9cup\u00e9r\u00e9 dans la mati\u00e8re r\u00e9colt\u00e9e et s\u00e9par\u00e9 des composants ind\u00e9sirables. Une s\u00e9quence de proc\u00e9d\u00e9 courante comprend la <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13418483\/\"><\/a><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13418483\/\">r\u00e9colte et la clarification, la chromatographie de capture, <\/a>puis des \u00e9tapes suppl\u00e9mentaires de purification et de concentration ou d\u2019\u00e9change de tampon.<\/p><p>La chromatographie sur prot\u00e9ine A est largement utilis\u00e9e pour capturer les anticorps appropri\u00e9s, mais la cha\u00eene de purification pr\u00e9cise d\u00e9pend du produit et du proc\u00e9d\u00e9. Cette m\u00e9thode utilise un mat\u00e9riau contenant de la prot\u00e9ine A, laquelle se lie \u00e0 une r\u00e9gion de nombreux anticorps. Lorsque le liquide r\u00e9colt\u00e9 traverse une colonne chromatographique, les anticorps appropri\u00e9s se fixent tandis que de nombreux autres composants passent au travers. Les anticorps captur\u00e9s sont ensuite lib\u00e9r\u00e9s pour poursuivre la purification.<\/p><p>\u00c0 ce stade, l\u2019anticorps purifi\u00e9 est consid\u00e9r\u00e9 comme une<strong> <a href=\"https:\/\/www.fda.gov\/media\/77528\/download\"><strong>substance active :<\/strong> <\/a><\/strong>la mati\u00e8re biologique active produite avant de devenir le m\u00e9dicament fini. Il peut ensuite \u00eatre <strong>formul\u00e9 <\/strong>avec d\u2019autres ingr\u00e9dients afin d\u2019atteindre la concentration et la stabilit\u00e9 requises, puis conditionn\u00e9 dans sa pr\u00e9sentation finale comme <strong>produit fini. <\/strong>Ces \u00e9tapes peuvent impliquer diff\u00e9rents \u00e9quipements et p\u00e9rim\u00e8tres de fabrication.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6156444 e-flex e-con-boxed e-con e-parent\" data-id=\"6156444\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-f81b0dd e-con-full e-flex e-con e-child\" data-id=\"f81b0dd\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2945566 e-flex e-con-boxed e-con e-parent\" data-id=\"2945566\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-efca5b2 elementor-widget elementor-widget-heading\" data-id=\"efca5b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Que doit contr\u00f4ler une installation de production lorsque les volumes augmentent ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9e2ccc3 elementor-widget elementor-widget-text-editor\" data-id=\"9e2ccc3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><strong>L\u2019augmentation de la production en culture cellulaire<\/strong> n\u2019accro\u00eet pas automatiquement la capacit\u00e9 de l\u2019ensemble du proc\u00e9d\u00e9. Une production plus \u00e9lev\u00e9e d\u2019anticorps dans les bior\u00e9acteurs signifie aussi <strong>davantage de mati\u00e8re \u00e0 r\u00e9colter<\/strong> et <strong>\u00e0 purifier.<\/strong> Si la capacit\u00e9 chromatographique, la pr\u00e9paration des tampons ou le temps disponible pour les op\u00e9rations aval ne suivent pas, ces \u00e9tapes peuvent <strong>limiter le d\u00e9bit global.<\/strong><\/li><li><strong>Les conditions upstream<\/strong> peuvent \u00e9galement modifier le profil d\u2019impuret\u00e9s ou les attributs qualit\u00e9 de la mati\u00e8re r\u00e9colt\u00e9e, ce qui influe sur le travail requis en aval. La capacit\u00e9 de production doit donc \u00eatre consid\u00e9r\u00e9e sur l\u2019ensemble du proc\u00e9d\u00e9 interconnect\u00e9 et non uniquement \u00e0 partir du rendement des bior\u00e9acteurs.<\/li><li>La <strong>s\u00e9curit\u00e9 et la qualit\u00e9 du produit<\/strong> structurent \u00e9galement le proc\u00e9d\u00e9. La <a href=\"https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q5A%28R2%29_Guideline_2023_1101.pdf\">version finale de la directive Q5A(R2) du Conseil international d\u2019harmonisation (ICH)<\/a> traite de l\u2019\u00e9valuation de la s\u00e9curit\u00e9 virale des produits biotechnologiques d\u00e9riv\u00e9s de lign\u00e9es cellulaires humaines ou animales, en incluant explicitement les anticorps monoclonaux. Elle d\u00e9crit des contr\u00f4les compl\u00e9mentaires portant sur les lign\u00e9es cellulaires et les mati\u00e8res premi\u00e8res, l\u2019\u00e9valuation de l\u2019\u00e9limination virale par le proc\u00e9d\u00e9 et les essais men\u00e9s aux \u00e9tapes de production appropri\u00e9es. L\u2019approche doit \u00eatre justifi\u00e9e pour le produit et le proc\u00e9d\u00e9 concern\u00e9s.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e782853 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"e782853\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-beb7812\" data-id=\"beb7812\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7e30b2c elementor-widget elementor-widget-heading\" data-id=\"7e30b2c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Quelles sont les avanc\u00e9es r\u00e9centes dans le domaine des anticorps monoclonaux ?<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-14e1427 elementor-widget elementor-widget-heading\" data-id=\"14e1427\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Que montrent les anticorps bisp\u00e9cifiques dans la recherche sur le my\u00e9lome multiple ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a4111bf elementor-widget elementor-widget-text-editor\" data-id=\"a4111bf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Le <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42294841\/\">talqu\u00e9tamab <\/a>est un anticorps bisp\u00e9cifique con\u00e7u pour se lier aux prot\u00e9ines GPRC5D pr\u00e9sentes sur les cellules du my\u00e9lome et aux prot\u00e9ines CD3 des cellules T, rapprochant ainsi les cellules immunitaires de leur cible. Dans l\u2019essai de phase 3 MonumenTAL-3 men\u00e9 en 2026, les associations de talqu\u00e9tamab et d\u2019autres anticorps ont obtenu une <em>survie sans progression <\/em>plus longue que le traitement comparateur chez des personnes atteintes d\u2019un my\u00e9lome multiple en rechute ou r\u00e9fractaire. Cela signifie que les patients ont v\u00e9cu plus longtemps sans aggravation de leur maladie, mais <strong>ne signifie pas<\/strong> qu\u2019ils ont \u00e9t\u00e9 gu\u00e9ris. Des \u00e9v\u00e9nements ind\u00e9sirables graves ont \u00e9t\u00e9 signal\u00e9s. Le rapport b\u00e9n\u00e9fice-risque doit donc \u00eatre consid\u00e9r\u00e9 parall\u00e8lement \u00e0 la s\u00e9curit\u00e9.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-44553f5 elementor-widget elementor-widget-heading\" data-id=\"44553f5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Que montre un essai de 2026 sur l\u2019h\u00e9mophilie A \u00e0 propos de la conception des anticorps ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-06b8cfc elementor-widget elementor-widget-text-editor\" data-id=\"06b8cfc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Le Mim8 (d\u00e9n\u00e9cimig) adopte une autre approche de la conception bisp\u00e9cifique : au lieu de rapprocher une cellule immunitaire d\u2019une tumeur, il est con\u00e7u pour rapprocher les facteurs de coagulation IXa et X, <a href=\"https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2517384\">imitant ainsi une fonction du facteur VIII activ\u00e9. <\/a>Dans l\u2019essai de phase 3 FRONTIER2 de 2026, les personnes recevant une prophylaxie hebdomadaire ou mensuelle par Mim8 ont pr\u00e9sent\u00e9 moins d\u2019\u00e9pisodes h\u00e9morragiques n\u00e9cessitant un traitement, ce qui constitue le r\u00e9sultat favorable, que celles trait\u00e9es uniquement lorsqu\u2019un saignement survenait. Dans une comparaison distincte, elles ont \u00e9galement pr\u00e9sent\u00e9 moins d\u2019\u00e9pisodes de ce type que lors de leur prophylaxie ant\u00e9rieure par facteur de coagulation.<\/p><p>L\u2019int\u00e9r\u00eat plus large r\u00e9side dans la <strong>diversit\u00e9 des fonctions que peut permettre une liaison \u00e0 deux cibles : <\/strong>le m\u00eame principe de conception d\u2019anticorps peut \u00eatre \u00e9tudi\u00e9 pour le traitement du cancer et pour la pr\u00e9vention des saignements, au moyen de m\u00e9canismes biologiques diff\u00e9rents.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-4e43b2c e-flex e-con-boxed e-con e-parent\" data-id=\"4e43b2c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a6ac833 e-con-full e-flex e-con e-child\" data-id=\"a6ac833\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-db05cf6 e-flex e-con-boxed e-con e-parent\" data-id=\"db05cf6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a6add77 elementor-widget elementor-widget-heading\" data-id=\"a6add77\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Comment la recherche sur la fabrication des mAb \u00e9volue-t-elle ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0ecf7c5 elementor-widget elementor-widget-text-editor\" data-id=\"0ecf7c5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>L\u2019innovation clinique s\u2019accompagne de recherches visant \u00e0 produire les anticorps plus efficacement. Une <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13418483\/\"><\/a><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13418483\/\">revue de 2026<\/a> publi\u00e9e sur les mAb examine la simulation des proc\u00e9d\u00e9s, l\u2019intensification de la culture cellulaire, les strat\u00e9gies alternatives de purification et les d\u00e9cisions de proc\u00e9d\u00e9 assist\u00e9es par l\u2019intelligence artificielle. Chacune r\u00e9pond \u00e0 une question pratique :<\/p><ul><li><strong>la simulation<\/strong> peut comparer les dimensions d\u2019\u00e9quipements ou les calendriers de production propos\u00e9s<\/li><li>la <strong>culture intensifi\u00e9e<\/strong> explore des moyens d\u2019augmenter la production<\/li><li>la <strong>recherche sur la purification<\/strong> \u00e9tudie la gestion de la r\u00e9cup\u00e9ration, des impuret\u00e9s et du co\u00fbt des \u00e9tapes de capture telles que la chromatographie sur prot\u00e9ine A<\/li><\/ul><p>Ces approches cr\u00e9ent aussi des compromis : une production accrue en amont peut <strong>augmenter la charge impos\u00e9e \u00e0 la purification, <\/strong>tandis qu\u2019un mod\u00e8le prometteur d\u00e9pend de la qualit\u00e9 des donn\u00e9es de proc\u00e9d\u00e9 utilis\u00e9es pour le construire et le tester. La revue identifie l\u2019h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des donn\u00e9es, la transf\u00e9rabilit\u00e9 limit\u00e9e entre proc\u00e9d\u00e9s et les contraintes r\u00e9glementaires comme des obstacles \u00e0 la mise en \u0153uvre.<\/p><p>La perspective utile pour les fabricants consiste donc \u00e0 mener une <strong>\u00e9valuation propre \u00e0 chaque proc\u00e9d\u00e9, <\/strong>plut\u00f4t qu\u2019\u00e0 supposer qu\u2019une nouvelle technique am\u00e9liorera le rendement, le co\u00fbt ou le temps de cycle de toutes les installations.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b32346e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b32346e\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f0094a3\" data-id=\"f0094a3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d5d3b11 elementor-widget elementor-widget-heading\" data-id=\"d5d3b11\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Comment Boccard accompagne-t-il les projets de production d\u2019anticorps monoclonaux ?<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ab95256 elementor-widget elementor-widget-text-editor\" data-id=\"ab95256\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Les \u00e9tapes de fabrication d\u00e9crites ci-dessus imposent des exigences aux \u00e9quipements de proc\u00e9d\u00e9 ainsi qu\u2019\u00e0 leur int\u00e9gration dans une installation.<\/p><p><strong>Boccard est un fournisseur de solutions EPCM de bout en bout et un partenaire de choix pour le march\u00e9 de <\/strong><strong><a href=\"https:\/\/www.boccard.com\/fr\/marches\/pharma-biotech\/\">pharmaceutiques et biotechnologie,<\/a><\/strong> qui <strong>con\u00e7oit pour construire et livrer des installations cl\u00e9s en main pour les projets brownfield et greenfield avec un TCO comp\u00e9titif.<\/strong> Pour un fabricant d\u2019anticorps monoclonaux, cela peut consister \u00e0 r\u00e9unir, dans un p\u00e9rim\u00e8tre convenu,<a href=\"https:\/\/www.boccard.com\/fr\/solutions\/ingenierie-travaux-neufs\/\"> l\u2019ing\u00e9nierie, <\/a>les <a href=\"https:\/\/www.boccard.com\/fr\/solutions\/genie-des-procedes\/\">\u00e9quipements de proc\u00e9d\u00e9<\/a> <a href=\"https:\/\/www.boccard.com\/fr\/solutions\/prefabrication-de-skids\/\">modulaires <\/a>et <a href=\"https:\/\/www.boccard.com\/fr\/solutions\/aide-a-la-performance-track-advance\/\">digitalis\u00e9s<\/a>, l\u2019int\u00e9gration des <a href=\"https:\/\/www.boccard.com\/fr\/solutions\/utilites-tuyauterie-propres-industrielles-pour-pharma-biotech\/\">utilit\u00e9s <\/a>ainsi que la <a href=\"https:\/\/www.boccard.com\/fr\/enjeux\/certifications-normes\/\">qualification <\/a>GMP, ou \u00e0 s\u00e9lectionner les \u00e9l\u00e9ments n\u00e9cessaires pour moderniser une ligne existante. L\u2019approche<strong> \u00ab menu \u00bb et \u00ab \u00e0 la carte \u00bb de Boccard<\/strong> permet d\u2019adapter l\u2019installation au proc\u00e9d\u00e9 du fabricant et \u00e0 son site existant, avec une responsabilit\u00e9 clairement d\u00e9finie pour les travaux r\u00e9alis\u00e9s par Boccard.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e43be3c elementor-widget elementor-widget-heading\" data-id=\"e43be3c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Que d\u00e9montre un projet sud-cor\u00e9en consacr\u00e9 aux mAb ?<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2c1b811 elementor-widget elementor-widget-text-editor\" data-id=\"2c1b811\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Un projet men\u00e9 <a href=\"https:\/\/www.boccard.com\/fr\/unite-de-production-danticorps-monoclonaux\/\">entre Boccard et son client en Cor\u00e9e du Sud<\/a> a d\u00e9montr\u00e9 l\u2019expertise et la contribution de Boccard dans les applications li\u00e9es aux anticorps monoclonaux. Boccard a r\u00e9alis\u00e9 les \u00e9tudes et fourni les \u00e9quipements de deux unit\u00e9s de production downstream d\u2019anticorps monoclonaux. Ses responsabilit\u00e9s comprenaient la conception, la gestion de projet, les achats et la mise en service sur site. Un partenaire cor\u00e9en a construit l\u2019installation \u00e0 partir des plans de Boccard.<\/p><p>Les \u00e9quipements fournis comprenaient <strong>13 skids de proc\u00e9d\u00e9<\/strong> int\u00e9grant <strong>48 cuves<\/strong> d\u2019une capacit\u00e9 comprise entre <strong>800 et 7 000 L,<\/strong> ainsi que <strong>6 skids de nettoyage<\/strong> int\u00e9grant <strong>20 cuves en acier inoxydable de 1 800 L.<\/strong> Cet exemple d\u00e9montre la livraison d\u2019un p\u00e9rim\u00e8tre couvrant les \u00e9quipements de proc\u00e9d\u00e9 downstream et de nettoyage. Pour en savoir plus, consultez <a href=\"https:\/\/www.boccard.com\/fr\/unite-de-production-danticorps-monoclonaux\/\">l\u2019\u00e9tude de cas de Boccard consacr\u00e9e \u00e0 cette unit\u00e9 de production d\u2019anticorps monoclonaux.<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e30319 elementor-widget elementor-widget-image\" data-id=\"6e30319\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"800\" height=\"645\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-1024x825.png\" class=\"attachment-large size-large wp-image-95045\" alt=\"\" srcset=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-1024x825.png 1024w, https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-300x242.png 300w, https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-768x619.png 768w, https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-1536x1237.png 1536w, https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_5_EN_10_2026-2048x1650.png 2048w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b637be1 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"b637be1\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-db882d4\" data-id=\"db882d4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-044c6e7 e-transform elementor-cta--skin-classic elementor-animated-content elementor-bg-transform elementor-bg-transform-zoom-in elementor-widget elementor-widget-call-to-action\" data-id=\"044c6e7\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_transform_scale_effect&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;_transform_scale_effect_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"call-to-action.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-cta\">\n\t\t\t\t\t<div class=\"elementor-cta__bg-wrapper\">\n\t\t\t\t<div class=\"elementor-cta__bg elementor-bg\" style=\"background-image: url(https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_2_EN_10_2026-1024x559.jpg);\" role=\"img\" aria-label=\"P&amp;B_Campaign_Monoclonal_Antibodies_2_EN_10_2026\"><\/div>\n\t\t\t\t<div class=\"elementor-cta__bg-overlay\"><\/div>\n\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-cta__content\">\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<h2 class=\"elementor-cta__title elementor-cta__content-item elementor-content-item\">\n\t\t\t\t\t\tEn savoir plus sur nos solutions pour<br \/>la Pharma &amp; Biotech ?\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-cta__button-wrapper elementor-cta__content-item elementor-content-item \">\n\t\t\t\t\t<a class=\"elementor-cta__button elementor-button elementor-size-\" href=\"https:\/\/www.boccard.com\/fr\/contact\/\">\n\t\t\t\t\t\tContactez-nous\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-415afe6 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"415afe6\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2edeb26\" data-id=\"2edeb26\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-bcd2852 elementor-widget elementor-widget-heading\" data-id=\"bcd2852\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Points cl\u00e9s<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-77fb1bf barre elementor-widget elementor-widget-heading\" data-id=\"77fb1bf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Les anticorps monoclonaux sont con\u00e7us pour <b>se lier \u00e0 des cibles biologiques sp\u00e9cifiques.<\/b> Les applications des anticorps bisp\u00e9cifiques et des anticorps conjugu\u00e9s \u00e0 un m\u00e9dicament incluent notamment le traitement du cancer et la prise en charge de l\u2019asthme s\u00e9v\u00e8re.<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-335f23d barre elementor-widget elementor-widget-heading\" data-id=\"335f23d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">La production industrielle relie la <b>culture cellulaire \u00e0 la r\u00e9cup\u00e9ration et \u00e0 la purification<\/b> des anticorps. L\u2019augmentation du rendement des bior\u00e9acteurs peut donc accro\u00eetre les exigences impos\u00e9es \u00e0 la capacit\u00e9 downstream.<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e8a6440 barre elementor-widget elementor-widget-heading\" data-id=\"e8a6440\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">La qualit\u00e9 du produit et la s\u00e9curit\u00e9 virale n\u00e9cessitent des <b>contr\u00f4les tout au long du proc\u00e9d\u00e9 de fabrication,<\/b> notamment l\u2019\u00e9valuation de la lign\u00e9e cellulaire, des mati\u00e8res premi\u00e8res et de l\u2019\u00e9limination virale.<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-410d017 barre elementor-widget elementor-widget-heading\" data-id=\"410d017\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Dans le cadre d\u2019un projet mAb en Cor\u00e9e du Sud, Boccard a fourni les \u00e9quipements de <b>2 unit\u00e9s de production downstream,<\/b> comprenant <b>13 skids de proc\u00e9d\u00e9<\/b> avec <b>48 cuves<\/b> et <b>6 skids de nettoyage avec 20 cuves en acier inoxydable.<\/b><\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-58a81d5 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"58a81d5\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cb6d518\" data-id=\"cb6d518\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-86b2451 elementor-widget elementor-widget-heading\" data-id=\"86b2451\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><b>Scope : \u00e9quipements et services fournis Ing\u00e9nierie &amp; pr\u00e9fabrication<\/b><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-8f93e77 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"8f93e77\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-edbf430\" data-id=\"edbf430\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-858bf2a elementor-widget elementor-widget-text-editor\" data-id=\"858bf2a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><a href=\"https:\/\/www.boccard.com\/fr\/solutions\/ingenierie-travaux-neufs\/\"><strong>Ing\u00e9nierie et r\u00e9alisation du projet :<\/strong><\/a> \u00e9tudes, conception, gestion de projet et achats pour deux unit\u00e9s de production aval d\u2019anticorps monoclonaux.<\/li><li><a href=\"https:\/\/www.boccard.com\/fr\/solutions\/genie-des-procedes\/\"><strong>\u00c9quipements de proc\u00e9d\u00e9 :<\/strong><\/a> <strong>13 skids de proc\u00e9d\u00e9<\/strong> int\u00e9grant <strong>48 cuves<\/strong> d\u2019une capacit\u00e9 comprise entre 800 et <strong>7 000 L,<\/strong> avec les plateformes associ\u00e9es.<\/li><li><a href=\"https:\/\/www.boccard.com\/fr\/solutions\/stations-nep-et-sep\/\"><strong>\u00c9quipements de nettoyage :<\/strong><\/a> 6 skids de nettoyage int\u00e9grant <strong>20 cuves en acier inoxydable de 1 800 L,<\/strong> ainsi que <strong>4 cuves en plastique<\/strong> destin\u00e9es au stockage des acides et de la soude.<\/li><li><a href=\"https:\/\/www.boccard.com\/fr\/solutions\/construction-revamping\/\"><strong>Construction et mise en service :<\/strong><\/a> un partenaire cor\u00e9en a construit l\u2019installation \u00e0 partir des plans de Boccard ; les \u00e9quipes Boccard ont r\u00e9alis\u00e9 la mise en service sur site.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-20c1b31 elementor-section-content-middle elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"20c1b31\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-65ee7a0b\" data-id=\"65ee7a0b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-34b52775 elementor-widget elementor-widget-heading\" data-id=\"34b52775\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Vous avez un projet ?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-3c6f0b8d\" data-id=\"3c6f0b8d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4817bf1d elementor-align-right elementor-mobile-align-center elementor-widget elementor-widget-button\" data-id=\"4817bf1d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.boccard.com\/fr\/contact\/\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contactez-nous<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-12631952 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"12631952\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-701d50b9\" data-id=\"701d50b9\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-67453d53 clair elementor-widget elementor-widget-heading\" data-id=\"67453d53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span class=\"lite\">Nos clients<\/span><br \/><span class=\"normal\">Ils<\/span> nous font confiance<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-12a29bd5 elementor-hidden-tablet elementor-hidden-mobile\" data-id=\"12a29bd5\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-1450d10f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1450d10f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2ff57334\" data-id=\"2ff57334\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3b5550ff clients elementor-widget elementor-widget-image-carousel\" data-id=\"3b5550ff\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;slides_to_show&quot;:&quot;5&quot;,&quot;navigation&quot;:&quot;none&quot;,&quot;image_spacing_custom&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:100,&quot;sizes&quot;:[]},&quot;slides_to_show_tablet&quot;:&quot;4&quot;,&quot;slides_to_show_mobile&quot;:&quot;2&quot;,&quot;autoplay&quot;:&quot;yes&quot;,&quot;pause_on_hover&quot;:&quot;yes&quot;,&quot;pause_on_interaction&quot;:&quot;yes&quot;,&quot;autoplay_speed&quot;:5000,&quot;infinite&quot;:&quot;yes&quot;,&quot;speed&quot;:500,&quot;image_spacing_custom_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;image_spacing_custom_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]}}\" data-widget_type=\"image-carousel.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-image-carousel-wrapper swiper\" role=\"region\" aria-roledescription=\"carousel\" aria-label=\"Image Carousel\" dir=\"ltr\">\n\t\t\t<div class=\"elementor-image-carousel swiper-wrapper\" aria-live=\"off\">\n\t\t\t\t\t\t\t\t<div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"1 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_LOre\u2560ual.jpg\" alt=\"Logo_LOre\u2560ual\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"2 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_Alstom-1.jpg\" alt=\"Logo_Alstom-1\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"3 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_bonduelle.jpg\" alt=\"Logo_bonduelle\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"4 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_EDF-1.jpg\" alt=\"Logo_EDF-1\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"5 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_Voltalia.jpg\" alt=\"Logo_Voltalia\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"6 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_ArcelorMittal.jpg\" alt=\"Logo_ArcelorMittal\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"7 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_AB_InBev.jpg\" alt=\"Logo_AB_InBev\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"8 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_Sanofi.jpg\" alt=\"Logo_Sanofi\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"9 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_Orano.jpg\" alt=\"Logo_Orano\" \/><\/figure><\/div><div class=\"swiper-slide\" role=\"group\" aria-roledescription=\"slide\" aria-label=\"10 sur 10\"><figure class=\"swiper-slide-inner\"><img decoding=\"async\" class=\"swiper-slide-image\" src=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/Logo_Danone-1.jpg\" alt=\"Logo_Danone-1\" \/><\/figure><\/div>\t\t\t<\/div>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-16275a69 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"16275a69\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3dbdff30\" data-id=\"3dbdff30\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-26d61c56 elementor-hidden-mobile elementor-widget elementor-widget-spacer\" data-id=\"26d61c56\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et la mani\u00e8re dont ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es cliniques r\u00e9centes ainsi que l\u2019expertise de Boccard en mati\u00e8re d\u2019\u00e9quipements de proc\u00e9d\u00e9, d\u2019int\u00e9gration d\u2019utilit\u00e9s et de r\u00e9alisation de projets conformes aux BPF (Bonnes Pratiques de Fabrication).<\/p>\n","protected":false},"author":29,"featured_media":95041,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38,69,39],"tags":[],"class_list":["post-95040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites","category-pharma-biotech","category-realisations"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard<\/title>\n<meta name=\"description\" content=\"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard\" \/>\n<meta property=\"og:description\" content=\"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/\" \/>\n<meta property=\"og:site_name\" content=\"Boccard\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T13:35:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-15T16:16:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png\" \/>\n\t<meta property=\"og:image:width\" content=\"980\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Orrick AFIANTO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Orrick AFIANTO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/\"},\"author\":{\"name\":\"Orrick AFIANTO\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#\\\/schema\\\/person\\\/15c263238afc7aa8f684ee1f0724c70a\"},\"headline\":\"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes\",\"datePublished\":\"2026-10-14T13:35:47+00:00\",\"dateModified\":\"2026-10-15T16:16:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/\"},\"wordCount\":2814,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png\",\"articleSection\":[\"Actualit\u00e9s\",\"Pharma &amp; Biotech\",\"R\u00e9alisations\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/\",\"url\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/\",\"name\":\"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png\",\"datePublished\":\"2026-10-14T13:35:47+00:00\",\"dateModified\":\"2026-10-15T16:16:08+00:00\",\"description\":\"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png\",\"contentUrl\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png\",\"width\":980,\"height\":640},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/\",\"name\":\"Boccard\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#organization\",\"name\":\"Boccard\",\"url\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/LOGO-BOCCARD-BLEU-SUR-FOND-TRANSPARENT.png\",\"contentUrl\":\"https:\\\/\\\/www.boccard.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/LOGO-BOCCARD-BLEU-SUR-FOND-TRANSPARENT.png\",\"width\":1423,\"height\":333,\"caption\":\"Boccard\"},\"image\":{\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/boccard\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/#\\\/schema\\\/person\\\/15c263238afc7aa8f684ee1f0724c70a\",\"name\":\"Orrick AFIANTO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g\",\"caption\":\"Orrick AFIANTO\"},\"sameAs\":[\"http:\\\/\\\/boccard.com\"],\"url\":\"https:\\\/\\\/www.boccard.com\\\/fr\\\/author\\\/afianto-orrick\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard","description":"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/","og_locale":"fr_FR","og_type":"article","og_title":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard","og_description":"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.","og_url":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/","og_site_name":"Boccard","article_published_time":"2026-10-14T13:35:47+00:00","article_modified_time":"2026-10-15T16:16:08+00:00","og_image":[{"width":980,"height":640,"url":"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png","type":"image\/png"}],"author":"Orrick AFIANTO","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Orrick AFIANTO","Dur\u00e9e de lecture estim\u00e9e":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#article","isPartOf":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/"},"author":{"name":"Orrick AFIANTO","@id":"https:\/\/www.boccard.com\/fr\/#\/schema\/person\/15c263238afc7aa8f684ee1f0724c70a"},"headline":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes","datePublished":"2026-10-14T13:35:47+00:00","dateModified":"2026-10-15T16:16:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/"},"wordCount":2814,"commentCount":0,"publisher":{"@id":"https:\/\/www.boccard.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png","articleSection":["Actualit\u00e9s","Pharma &amp; Biotech","R\u00e9alisations"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/","url":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/","name":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes - Boccard","isPartOf":{"@id":"https:\/\/www.boccard.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#primaryimage"},"image":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png","datePublished":"2026-10-14T13:35:47+00:00","dateModified":"2026-10-15T16:16:08+00:00","description":"D\u00e9couvrez le fonctionnement des anticorps monoclonaux, les pathologies qu\u2019ils permettent de traiter et comment ils sont produits \u00e0 grande \u00e9chelle. Explorez les avanc\u00e9es r\u00e9centes sur le plan clinique et en mati\u00e8re de production.","breadcrumb":{"@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#primaryimage","url":"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png","contentUrl":"https:\/\/www.boccard.com\/wp-content\/uploads\/2026\/10\/PB_Campaign_Monoclonal_Antibodies_7_EN_10_2026.png","width":980,"height":640},{"@type":"BreadcrumbList","@id":"https:\/\/www.boccard.com\/fr\/anticorps-monoclonaux-utilisations-production-et-avancees-recentes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.boccard.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Anticorps monoclonaux : utilisations, production et avanc\u00e9es r\u00e9centes"}]},{"@type":"WebSite","@id":"https:\/\/www.boccard.com\/fr\/#website","url":"https:\/\/www.boccard.com\/fr\/","name":"Boccard","description":"","publisher":{"@id":"https:\/\/www.boccard.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.boccard.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.boccard.com\/fr\/#organization","name":"Boccard","url":"https:\/\/www.boccard.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.boccard.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/LOGO-BOCCARD-BLEU-SUR-FOND-TRANSPARENT.png","contentUrl":"https:\/\/www.boccard.com\/wp-content\/uploads\/2023\/08\/LOGO-BOCCARD-BLEU-SUR-FOND-TRANSPARENT.png","width":1423,"height":333,"caption":"Boccard"},"image":{"@id":"https:\/\/www.boccard.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/boccard"]},{"@type":"Person","@id":"https:\/\/www.boccard.com\/fr\/#\/schema\/person\/15c263238afc7aa8f684ee1f0724c70a","name":"Orrick AFIANTO","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3224ac1994228abc5fb659873e7e7d34636dcc8b1ea1293792bd0a945d234209?s=96&d=mm&r=g","caption":"Orrick AFIANTO"},"sameAs":["http:\/\/boccard.com"],"url":"https:\/\/www.boccard.com\/fr\/author\/afianto-orrick\/"}]}},"_links":{"self":[{"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/posts\/95040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/comments?post=95040"}],"version-history":[{"count":15,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/posts\/95040\/revisions"}],"predecessor-version":[{"id":95062,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/posts\/95040\/revisions\/95062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/media\/95041"}],"wp:attachment":[{"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/media?parent=95040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/categories?post=95040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.boccard.com\/fr\/wp-json\/wp\/v2\/tags?post=95040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}